scholarly journals Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma

2018 ◽  
Vol 2 (13) ◽  
pp. 1595-1607 ◽  
Author(s):  
James L. Rubenstein ◽  
Huimin Geng ◽  
Eleanor J. Fraser ◽  
Paul Formaker ◽  
Lingjing Chen ◽  
...  
Keyword(s):  
Phase 1 ◽  
Response Duration ◽  
Cns Lymphoma ◽  
Key Points ◽  
Cns Lymphomas

Key Points Lenalidomide penetrates ventricular CSF and is active as monotherapy in relapsed CNS lymphomas. Maintenance lenalidomide is feasible and may potentiate response duration after salvage in relapsed PCNSL and delay WBRT.

scholarly journals Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Blood ◽  
2013 ◽  
Vol 121 (5) ◽  
pp. 745-751 ◽  
Author(s):  
James L. Rubenstein ◽  
Jing Li ◽  
Lingjing Chen ◽  
Ranjana Advani ◽  
Jan Drappatz ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Phase 1 ◽  
Cns Lymphoma ◽  
Phase 1 Trial ◽  
Multicenter Phase ◽  
Key Points

Key Points Phase I study showed that intraventricular rituximab plus methotrexate is feasible and active in the treatment of refractory CNS lymphoma.

scholarly journals A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2308-2316 ◽  
Author(s):  
David H. McDermott ◽  
Qian Liu ◽  
Daniel Velez ◽  
Lizbeeth Lopez ◽  
Sandra Anaya-O’Brien ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Low Dose ◽  
Phase 1 ◽  
Cxcr4 Antagonist ◽  
Phase 1 Clinical Trial ◽  
Dose Treatment ◽  
Whim Syndrome ◽  
Key Points

Key Points Plerixafor can be given safely to WHIM syndrome patients twice daily for a 6-month period and appears promising as a treatment.

scholarly journals [18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 1137
Author(s):  
Kirsty Marshall ◽  
Bhupinder Sharma ◽  
Thomas Millard ◽  
Sahil Chhabda ◽  
Fayed Sheikh ◽  
...  
Keyword(s):  
Grey Matter ◽  
Response Assessment ◽  
Complete Response ◽  
Cns Lymphoma ◽  
Residual Tumour ◽  
Alternative Mode ◽  
Positron Emission ◽  
Pet Ct ◽  
Magnetic Resonance Imaging Mri ◽  
Cns Lymphomas

Background Central nervous system (CNS) lymphomas are a rare subset of lymphoma, which are associated with a poor outcome. The gold standard for CNS imaging is with gadolinium-enhanced magnetic resonance imaging (MRI); however, there are a number of limitations, including some patients with small persistent abnormalities from scarring due to focal haemorrhage or from a previous biopsy, which can be difficult to discern from residual tumour. [18F]Fluoromethylcholine positron emission tomography–computed tomography (FCH-PET/CT) uses an analogue of choline, which due to the upregulation of choline kinase in tumour cells, allows increased uptake of FCH. As there is minimal background grey matter uptake of FCH, FCH-PET/CT can be used in CNS imaging and provide a useful tool for response assessment. Methods This is a cohort study, where we identified 40 patients with a diagnosis of primary or secondary CNS lymphoma between 1st November 2011 and 10th October 2019. Results 26 of the 40 patients (65%) had concordant results. Of the discordant results, 11 out of 14 had partial response (PR) on MRI but showed a metabolic complete response (mCR) on FCH-PET. The overall response rates (ORR) were similar between the two modalities (90% for MRI versus 95% with FCT-PET/CT). Conclusion We conclude that FCH-PET/CT is a reasonable alternative mode of imaging to gadolinium-enhanced MRI brain imaging, providing a new tool for assessment of CNS lymphoma.

scholarly journals Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Blood ◽  
2018 ◽  
Vol 131 (21) ◽  
pp. 2331-2334 ◽  
Author(s):  
Robert J. Kreitman ◽  
Martin S. Tallman ◽  
Tadeusz Robak ◽  
Steven Coutre ◽  
Wyndham H. Wilson ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Aspirate ◽  
Phase 1 ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Key Points ◽  
Long Term Follow Up ◽  
Minimal Residual

Key Points Moxetumomab pasudotox eradicated HCL MRD in >50% of CRs, even by the most sensitive measure, bone marrow aspirate flow cytometry. Elimination of MRD was significantly associated with prolonged CR duration.

scholarly journals BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

2019 ◽  
Vol 3 (22) ◽  
pp. 3740-3749 ◽  
Author(s):  
Tsila Zuckerman ◽  
Ron Ram ◽  
Luiza Akria ◽  
Maya Koren-Michowitz ◽  
Ron Hoffman ◽  
...  
Keyword(s):  
Older Adults ◽  
Acute Leukemia ◽  
Phase 1 ◽  
Intensive Therapy ◽  
High Dose ◽  
Term Survival ◽  
Long Term Survival ◽  
Key Points ◽  
High Dose Cytarabine

Key Points The majority of older adults or unfit acute leukemia patients are not offered intensive therapy, resulting in dismal long-term survival. A novel cytarabine prodrug BST-236 enables delivery of high-dose cytarabine and appears to be safe and efficacious in these patients.

Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival.

1985 ◽  
Vol 3 (4) ◽  
pp. 490-494 ◽  
Author(s):  
J S Loeffler ◽  
T J Ervin ◽  
P Mauch ◽  
A Skarin ◽  
H J Weinstein ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Systemic Disease ◽  
Cns Lymphoma ◽  
Primary Lymphoma ◽  
Patterns Of Failure ◽  
Craniospinal Radiation ◽  
The Central Nervous System ◽  
Joint Center ◽  
Hodgkin's Lymphomas ◽  
Cns Lymphomas

Primary lymphomas of the CNS are rare tumors accounting for less than 2% of all extranodal non-Hodgkin's lymphomas. The treatment for this disease has been disappointing. Radiation therapy and surgery have produced consistently poor control of this disease, with a median survival of 15 months. We have reviewed ten cases of primary lymphoma of the CNS treated at the Joint Center for Radiation Therapy or Dana-Farber Cancer Institute (Boston) from 1968 to 1981. All patients had biopsy-proven CNS lymphomas without systemic disease at presentation. In our series, control of CNS lymphoma was seen only in patients receiving craniospinal radiation or CNS-penetrating chemotherapy.

scholarly journals Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood ◽  
2016 ◽  
Vol 128 (19) ◽  
pp. 2297-2306 ◽  
Author(s):  
Inger S. Nijhof ◽  
Laurens E. Franssen ◽  
Mark-David Levin ◽  
Gerard M. J. Bos ◽  
Annemiek Broijl ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 1 ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points REP is an active combination in MM patients refractory to lenalidomide. REP is an all-oral and generally well-tolerated regimen.

scholarly journals Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease

Blood ◽  
2017 ◽  
Vol 129 (24) ◽  
pp. 3256-3261 ◽  
Author(s):  
Yi-Bin Chen ◽  
Miguel-Angel Perales ◽  
Shuli Li ◽  
Maria Kempner ◽  
Carol Reynolds ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Phase 1 ◽  
Multicenter Trial ◽  
Brentuximab Vedotin ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points ◽  
Steroid Refractory ◽  
Acute Graft

Key Points BV has activity for SR-aGVHD. The MTD of BV was 0.8 mg/kg every 2 weeks for 4 doses.

scholarly journals First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Blood ◽  
2018 ◽  
Vol 131 (23) ◽  
pp. 2515-2527 ◽  
Author(s):  
Rizwan Romee ◽  
Sarah Cooley ◽  
Melissa M. Berrien-Elliott ◽  
Peter Westervelt ◽  
Michael R. Verneris ◽  
...  
Keyword(s):  
T Cells ◽  
Clinical Study ◽  
Cell Expansion ◽  
Phase 1 ◽  
Single Agent ◽  
Cd8 T Cell ◽  
Key Points ◽  
Clinical Responses ◽  
Human Use

Key Points Single-agent IL-15/IL-15Rα-Fc (ALT-803) therapy was well tolerated and resulted in clinical responses in patients who relapsed post-HCT. First-in-human use of ALT-803 promoted NK and CD8+ T-cell expansion and activation in vivo without stimulating regulatory T cells.

Sign in / Sign up

Export Citation Format

Share Document